A Retrospective Analysis of the Efficacy of Risperidone in People with Developmental Disabilities Living in Institutional Settings

Theodore A. Kastner, Kevin K. Walsh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study retrospectively examined the efficacy of the atypical antipsychotic risperidone in people with developmental disabilities living in institutional settings. Specifically, this study examined the impact of risperidone on clinical global impression (CGI) ratings of medical/psychiatric and behavioral status and other clinical measures. The study collected data from 294 individuals receiving either risperidone or haloperidol, alone or in combination with other psychotropic medications, from a population residing in several state-run, ICF/MR-certified developmental centers in one state. Comparisons were made on retrospective data between those receiving risperidone and those receiving haloperidol on several measures based on intensive record reviews. Clinical characteristics of subjects were related to psychotropic medications and specifically to dose ranges. Significant differences were obtained on both medical and behavioral CGI measures between the risperidone and haloperidol groups. Implications of these and other findings are discussed.

Original languageEnglish (US)
Pages (from-to)10-20
Number of pages11
JournalMental Health Aspects of Developmental Disabilities
Volume7
Issue number1
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Developmental Disabilities
Risperidone
Disabled Persons
Haloperidol
Antipsychotic Agents
Psychiatry
Population

Keywords

  • Atypical antipsychotics
  • Clinical global impressions
  • Developmental disabilities
  • Institutional settings
  • Intellectual disability
  • Mental retardation
  • Psychiatric disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A Retrospective Analysis of the Efficacy of Risperidone in People with Developmental Disabilities Living in Institutional Settings. / Kastner, Theodore A.; Walsh, Kevin K.

In: Mental Health Aspects of Developmental Disabilities, Vol. 7, No. 1, 01.2004, p. 10-20.

Research output: Contribution to journalArticle

@article{eb4d6be304e041e1bc70fea7aa8b986f,
title = "A Retrospective Analysis of the Efficacy of Risperidone in People with Developmental Disabilities Living in Institutional Settings",
abstract = "This study retrospectively examined the efficacy of the atypical antipsychotic risperidone in people with developmental disabilities living in institutional settings. Specifically, this study examined the impact of risperidone on clinical global impression (CGI) ratings of medical/psychiatric and behavioral status and other clinical measures. The study collected data from 294 individuals receiving either risperidone or haloperidol, alone or in combination with other psychotropic medications, from a population residing in several state-run, ICF/MR-certified developmental centers in one state. Comparisons were made on retrospective data between those receiving risperidone and those receiving haloperidol on several measures based on intensive record reviews. Clinical characteristics of subjects were related to psychotropic medications and specifically to dose ranges. Significant differences were obtained on both medical and behavioral CGI measures between the risperidone and haloperidol groups. Implications of these and other findings are discussed.",
keywords = "Atypical antipsychotics, Clinical global impressions, Developmental disabilities, Institutional settings, Intellectual disability, Mental retardation, Psychiatric disorder",
author = "Kastner, {Theodore A.} and Walsh, {Kevin K.}",
year = "2004",
month = "1",
language = "English (US)",
volume = "7",
pages = "10--20",
journal = "Mental Health Aspects of Developmental Disabilities",
issn = "1057-3291",
publisher = "Psych-Media Inc.",
number = "1",

}

TY - JOUR

T1 - A Retrospective Analysis of the Efficacy of Risperidone in People with Developmental Disabilities Living in Institutional Settings

AU - Kastner, Theodore A.

AU - Walsh, Kevin K.

PY - 2004/1

Y1 - 2004/1

N2 - This study retrospectively examined the efficacy of the atypical antipsychotic risperidone in people with developmental disabilities living in institutional settings. Specifically, this study examined the impact of risperidone on clinical global impression (CGI) ratings of medical/psychiatric and behavioral status and other clinical measures. The study collected data from 294 individuals receiving either risperidone or haloperidol, alone or in combination with other psychotropic medications, from a population residing in several state-run, ICF/MR-certified developmental centers in one state. Comparisons were made on retrospective data between those receiving risperidone and those receiving haloperidol on several measures based on intensive record reviews. Clinical characteristics of subjects were related to psychotropic medications and specifically to dose ranges. Significant differences were obtained on both medical and behavioral CGI measures between the risperidone and haloperidol groups. Implications of these and other findings are discussed.

AB - This study retrospectively examined the efficacy of the atypical antipsychotic risperidone in people with developmental disabilities living in institutional settings. Specifically, this study examined the impact of risperidone on clinical global impression (CGI) ratings of medical/psychiatric and behavioral status and other clinical measures. The study collected data from 294 individuals receiving either risperidone or haloperidol, alone or in combination with other psychotropic medications, from a population residing in several state-run, ICF/MR-certified developmental centers in one state. Comparisons were made on retrospective data between those receiving risperidone and those receiving haloperidol on several measures based on intensive record reviews. Clinical characteristics of subjects were related to psychotropic medications and specifically to dose ranges. Significant differences were obtained on both medical and behavioral CGI measures between the risperidone and haloperidol groups. Implications of these and other findings are discussed.

KW - Atypical antipsychotics

KW - Clinical global impressions

KW - Developmental disabilities

KW - Institutional settings

KW - Intellectual disability

KW - Mental retardation

KW - Psychiatric disorder

UR - http://www.scopus.com/inward/record.url?scp=1842473244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842473244&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:1842473244

VL - 7

SP - 10

EP - 20

JO - Mental Health Aspects of Developmental Disabilities

JF - Mental Health Aspects of Developmental Disabilities

SN - 1057-3291

IS - 1

ER -